Alembic Pharma Key Ratios
NSE: APLLTD | BSE: 533573
₹1,044.35
As on 18-Nov-2026IST
Market cap
₹20,512 Cr
Revenue (TTM)
₹8,477 Cr
P/E Ratio
24.3
P/B Ratio
3.5
Div. Yield
1.1 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 21.11 | 36.30 | 19.68 | 12.23 | 10.21 |
| EBIT | 97.51 | 93.00 | 24.88 | 20.92 | 1.97 |
| Net Profit | 93.66 | 81.46 | 45.18 | 20.10 | 1.10 |
| EPS | 93.66 | 81.46 | 33.02 | 16.65 | -0.65 |
| Book Value | -- | -- | 9.32 | 9.10 | 2.29 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| 10.78 | 10.21 | 12.38 | 10.88 | 10.86 |
| Net Margin
| 9.19 | 8.67 | 9.84 | 9.07 | 8.66 |
| Return on equity
| 12.46 | 10.92 | 15.85 | 12.35 | 11.63 |
| Return on Capital
| 12.89 | 11.47 | -- | 11.74 | 13.51 |
| Return on Assets
| 8.82 | 7.79 | 9.39 | 8.23 | 8.28 |
| Debt to Equity (x)
| -- | -- | 0.02 | 0.24 | 0.23 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
--
|
11.74
|
13.51
|
13.42
|
7.44
|
|
Peer Median
|
--
|
14.77
|
14.72
|
18.85
|
--
|
ROE
15.85
Higher than Peers by 5.09
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
15.85
|
12.35
|
11.63
|
13.40
|
7.12
|
|
Peer Median
|
10.76
|
12.35
|
11.67
|
14.92
|
--
|
ROA
9.39
Higher than Peers by 2.67
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
9.39
|
8.23
|
8.28
|
9.93
|
5.15
|
|
Peer Median
|
6.72
|
6.87
|
7.86
|
9.06
|
--
|
EBIT Margin
12.38
Lower than Peers by 0.38
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
12.38
|
10.88
|
10.86
|
10.60
|
7.65
|
|
Peer Median
|
12.75
|
13.55
|
15.03
|
14.71
|
--
|
Net Margin
9.84
Higher than Peers by 0.78
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
9.84
|
9.07
|
8.66
|
9.84
|
6.05
|
|
Peer Median
|
9.06
|
8.30
|
9.33
|
8.49
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
--
|
6.94
|
6.42
|
6.61
|
10.92
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
19.68
Higher than Peers by 10.83
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
19.68
|
10.08
|
7.12
|
10.19
|
6.54
|
|
Peer Median
|
8.85
|
17.50
|
10.27
|
11.85
|
--
|
EBIT Growth
24.88
Higher than Peers by 7.63
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
24.88
|
10.37
|
9.76
|
52.55
|
-26.34
|
|
Peer Median
|
17.24
|
24.88
|
24.15
|
28.00
|
--
|
Net Profit Growth
45.18
Higher than Peers by 27.93
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
45.18
|
15.26
|
-5.49
|
80.07
|
-34.35
|
|
Peer Median
|
17.25
|
36.93
|
30.29
|
36.51
|
--
|
EPS Growth
33.02
Higher than Peers by 23.16
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
33.02
|
15.66
|
-5.26
|
80.07
|
-34.35
|
|
Peer Median
|
9.87
|
26.79
|
24.50
|
--
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
--
|
9.32
|
7.74
|
10.24
|
-16.55
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.02
Lower than Peers by 0.02
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
0.02
|
0.24
|
0.23
|
0.09
|
0.15
|
|
Peer Median
|
0.04
|
0.24
|
0.23
|
0.20
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
--
|
0.21
|
0.23
|
0.09
|
0.15
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.69
Lower than Peers by 0.08
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
1.69
|
1.73
|
1.67
|
2.07
|
1.78
|
|
Peer Median
|
1.76
|
1.83
|
1.79
|
1.96
|
--
|
Quick Ratio
0.83
Lower than Peers by 0.37
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
0.83
|
0.79
|
0.76
|
0.99
|
0.88
|
|
Peer Median
|
1.20
|
1.19
|
1.47
|
1.44
|
--
|
Interest Coverage
9.43
Higher than Peers by 1.31
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
9.43
|
8.41
|
9.98
|
12.24
|
8.07
|
|
Peer Median
|
8.12
|
7.74
|
9.42
|
8.58
|
--
|
Operating Efficiency
Debtors to sales
22.37
Lower than Peers by 2.93
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
22.37
|
19.96
|
20.98
|
16.45
|
18.51
|
|
Peer Median
|
25.30
|
23.05
|
25.82
|
26.12
|
--
|
Asset Turnover
0.95
Higher than Peers by 0.28
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
0.95
|
1.75
|
1.91
|
2.17
|
0.85
|
|
Peer Median
|
0.66
|
0.79
|
0.75
|
0.77
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
--
|
36.70
|
32.99
|
28.10
|
59.84
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
--
|
61.45
|
53.50
|
42.32
|
99.60
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
--
|
157.72
|
164.40
|
150.62
|
148.04
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
--
|
-59.57
|
-77.92
|
-80.19
|
11.40
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
24.31
Lower than Peers by 19.17
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
24.31
|
19.28
|
31.31
|
31.35
|
28.50
|
|
Peer Median
|
43.48
|
43.48
|
39.70
|
33.48
|
--
|
Price / Book Value
3.45
Lower than Peers by 0.46
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
3.45
|
2.29
|
3.52
|
4.01
|
2.23
|
|
Peer Median
|
3.91
|
4.07
|
3.72
|
4.21
|
--
|
Dividend Yield
1.15
Higher than Peers by 0.96
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
1.15
|
1.81
|
1.18
|
1.12
|
1.61
|
|
Peer Median
|
0.19
|
0.09
|
0.16
|
0.21
|
--
|
EV/EBITDA
14.61
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
14.61
|
12.08
|
18.43
|
20.39
|
14.49
|
|
Peer Median
|
--
|
32.90
|
30.23
|
29.90
|
--
|
Market Cap
20,512
Higher than Peers by 11,340
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Alembic Pharma
|
20,512
|
13,009
|
18,264
|
19,308
|
9,748
|
|
Peer Median
|
9,173
|
4,938
|
4,851
|
2,099
|
--
|